报告名称：Yestar International(02393.HK)In-vitro diagnostic devices to drive strong earnin
报告类型：港股研究
报告日期：2016-03-15
研究机构：唯高达香港证券有限公司
股票名称：巨星国际控股
股票代码：02393
页数：5
简介：Driven by the acquisition of in-vitro diagnostic (IVD) devices distributor, Yestar’s FY15 earnings surged by 61% to Rmb163m, 6% above our estimates
Expect EPS CAGR of 28% in FY15-17F driven by further penetration of its IVD products into mid/basic level hospitals
We believe Yestar is actively looking for M&A targets in IVD industry. Successful M&A can accelerate earnings growth. Maintain BUY with TP unchanged at HK$4.00

下载地址：Yestar International(02393.HK)In-vitro diagnostic devices to drive strong earnin